ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Wien (euro adhoc) - Vienna (Austria), December 15, 2006 - Intercell AG (VSE, "ICLL") announced today the following realignment in its Supervisory Board: Hans Küpper, who represented the private equity firm Global Life Science Ventures on Intercells Supervisory Board, resigns from his position resigned ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.12.2006 » Phase II combination trial for therapeutic Hepatitis C vaccine (IC41) completed. Started in 2003 the study was still conducted with a not optimized vaccination schedule. » ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 06.12.2006 » Vienna-based Pelias AG focuses on the development of novel vaccines against hospital-acquired infections - the companys lead product, a novel protein based vaccine against ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 13.11.2006 Latest Achievements: » EU Grant of EUR 2.3 million for the development of an otitis media vaccine » EU Grant of EUR 3.5 million for the development of a pandemic influenza ...
EUR 2.3 million funding by the European Commission ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Wien (euro adhoc) - » Coordination of a European consortium of academic and commercial partners to develop a vaccine against the childhood disease otitis media (Middle ear infection) » ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 26.10.2006 » Agreement includes a USD 9.5 million upfront payment, up to USD 76 million milestone payments as well as royalties on future net sales of the product Intercell AG (VSE "ICLL") ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Intercell AG was honoured with the first price in the final round of the Biotechnica Award 2006 during yesterdays ceremony at the Biotech CEO Conference in Zürich. The Biotechnica Award, endowed with 40,000 Euros, is awarded by the Deutsche Messe AG for the fourth time to European biotech and life science ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.10.2006 » Successful pre-BLA meeting with the FDA in September 2006 » Intercell has now initiated the regulatory process towards a Biologics License Application (BLA) for its Japanese ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 02.10.2006 Michel Gréco was elected new chairman in Intercells meeting of the supervisory board. He is taking over the function from Ernst Günter Afting, who in future will serve as ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 26.09.2006 » Start of a further Phase II clinical trial in chronic Hepatitis C patients using the optimized route and frequency of administration identified in the recent optimization ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.09.2006 » Worldwide agreement with Wyeth for the use of Intercell's fully synthetic novel adjuvant IC31TM in various selected infectious disease vaccine programs » Up to USD 77 million ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 06.09.2006 » Support from PATH for the development of Intercell's Streptococcus pneumoniae candidate vaccine - USD 7.3 m initial funding through preclinical stage, leading to a vaccine ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 24.08.2006 » Results for Intercells Japanese Encephalitis virus vaccine in the pivotal Phase III safety trial, which included 2,683 randomized subjects, are positive » Intercells JE ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 11.08.2006 Significant clinical progress: » Positive results for Intercells Japanese Encephalitis Virus vaccine in pivotal clinical Phase III immunogenicity trial - primary endpoint met ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 03.08.2006 Intercell AG (VSE, "ICLL") today announced the recruitment of Thomas Lingelbach as Chief Operating Officer of Intercell and Managing Director of Intercell Biomedical Ltd. (Scotland), the operating site for the commercial production of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 07.07.2006 Intercell announced today that Merrill Lynch International, the underwriter of its recent public offering of common shares, has exercised in full the over-allotment option which was ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 30.06.2006 Not for distribution in the United States, Canada and Japan Intercell AG, a vaccine company based in Austria, announced today the successful placement of 7.8 million primary and ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 13.06.2006 Intercell AG, a vaccine company based in Austria, announced today the launch of a public offering for up to 7.8 million primary and secondary shares. Subject to the approval of the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.06.2006 » Intercell has agreed to enter into an agreement with Novartis for the marketing and distribution of its Japanese Encephalitis Vaccine (IC51) in the United States, Europe and ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 31.05.2006 » First results for Intercells Japanese Encephalitis virus vaccine in the pivotal immunogenicity clinical trial are positive » In a preliminary statistical analysis, the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 15.05.2006 Intercell AG (VSE, "ICLL") today announced that the following persons have been appointed new members of the supervisory board in the course of Intercells Annual General Meeting on ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 11.05.2006 Intercell AG (VSE "ICLL") today announced that it has entered into a strategic partnership with Merck & Co., Inc. to develop human monoclonal antibodies against severe infections ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 08.05.2006 Product development progress: » Japanese Encephalitis: Recruitment for pivotal Phase III study completed - Orphan Drug Status granted by the European Commission - Positive ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 26.04.2006 Intercell (VSE, "ICLL") announced today that the European Patent Office has granted an additional key patent covering a component of Intercells novel proprietary synthetic adjuvant ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 20.04.2006 Intercell AG (VSE, "ICLL") publishes its Annual Report for the 2005 financial year today. The illustrated Annual Report gives detailed information on Intercells latest achievements, its product candidates, its technologies and it also ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 06.04.2006 » Monoclonal antibodies against bacterial infections - a novel use for Intercell's technologies with significant potential in anti-infection applications, in addition to their ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 06.03.2006 Intercell announces preliminary 2005 full year results: Good progress in product development - significant increase in revenues - strong cash position Financials: » Preliminary ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 21.02.2006 Intercell AG (VSE, "ICLL") announced today that the recruitment for the pivotal immunogenicity Phase III trial of its Japanese Encephalitis vaccine has successfully been completed ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 14.02.2006 Intercell AG announced today the appointment of its new Scientific Advisory Board (SAB). The company feels honored that the following academic scientists have accepted the invitation to serve in Intercell's new SAB: Rafi Ahmed (Emory ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 03.02.2006 Vienna (Austria), February 3, 2006 - Intercell AG (VSE, "ICLL") today announced the following realignment in its Supervisory Board: Luke Evnin, general partner at the private equity firm MPM Capital L.P., who joined Intercells ...